# US 2019/0375838 A1 · Proteins binding bcma, nkg2d and cd16

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375838 A1
- Document ID: US20190375838A1
- Status: Published application
- Kind: A1
- Application number: 16/484,936
- Filed: 2018-02-09
- Published: 2019-12-12
- Earliest claimed: 2017-02-10
- Assignees: Dragonfly Therapeutics, Inc.
- Applicants: Dragonfly Therapeutics, Inc.
- Inventors: Gregory P. CHANG; Ann F. CHEUNG; William HANEY; Bradley M. LUNDE; Bianka PRINZ
- Web page: https://patentgrep.com/patent/US20190375838A1

## CPC

- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61P 35/00: Antineoplastic agents
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/526: CH3 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/624: Disulfide-stabilized antibody (dsFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/66: comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Multi-specific binding proteins that bind BCMA, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

## Claims

### Claim 1

A protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds BCMA; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16.

### Claim 2 (depends on 1)

The protein of claim 1, wherein the first antigen-binding site binds to NKG2D in humans, non-human primates, and rodents.

### Claim 3 (depends on 1, 2)

The protein of claim 1 or 2, wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.

### Claim 4 (depends on 3)

A protein according to claim 3, wherein the heavy chain variable domain and the light chain variable domain are present on the same polypeptide.

### Claim 5 (depends on 3, 4)

A protein according to any one of claims 3-4, wherein the second antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.

### Claim 6 (depends on 5)

A protein according to claim 5, wherein the heavy chain variable domain and the light chain variable domain of the second antigen-binding site are present on the same polypeptide.

### Claim 7 (depends on 5, 6)

A protein according to claim 5 or 6, wherein the light chain variable domain of the first antigen-binding site has an amino acid sequence identical to the amino acid sequence of the light chain variable domain of the second antigen-binding site.

### Claim 8

A protein according to any one of the preceding claims, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO: 1.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

A protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:41 and a light chain variable domain at least 90% identical to SEQ ID NO:42.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

A protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:43 and a light chain variable domain at least 90% identical to SEQ ID NO:44.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7)

A protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:45 and a light chain variable domain at least 90% identical to SEQ ID NO:46.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

A protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:47 and a light chain variable domain at least 90% identical to SEQ ID NO:48.

### Claim 13 (depends on 1, 2)

The protein of claim 1 or 2, wherein the first antigen-binding site is a single-domain antibody.

### Claim 14 (depends on 13)

The protein of claim 13, wherein the single-domain antibody is a VHH fragment or a VNAR fragment.

### Claim 15 (depends on 1, 2, 13, 14)

A protein according to any one of claims 1-2 or 13-14, wherein the second antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.

### Claim 16 (depends on 15)

A protein according to claim 15, wherein the heavy chain variable domain and the light chain variable domain of the second antigen-binding site are present on the same polypeptide.

### Claim 17

A protein according to any of the preceding claims, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:49 and the light chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:53 or SEQ ID NO:54.

### Claim 18

A protein according to any of the preceding claims, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence including:
a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:50;
a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:51; and
a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:52.

### Claim 19 (depends on 18)

A protein according to claim 18, wherein the light chain variable domain of the second antigen-binding site comprises an amino acid sequence including:
a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:55;
a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:56; and
a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:57 or SEQ ID NO:57.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A protein according to any one of claims 1-16, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:59 and the light chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:60.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20)

A protein according to any one of claims 1-16 or 20, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence including:
a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:79;
a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:80; and
a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:81.

### Claim 22 (depends on 21)

A protein according to claim 21, wherein the light chain variable domain of the second antigen-binding site comprises an amino acid sequence including:
a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:82;
a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:83; and
a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:84.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A protein according to any one of claims 1-16, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:61 and the light chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:62.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 23)

A protein according to any one of claims 1-16 or 23, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence including:
a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:85;
a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:86; and
a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:87.

### Claim 25 (depends on 24)

A protein according to any one of claim 24, wherein the light chain variable domain of the second antigen-binding site comprises an amino acid sequence including:
a light chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:88;
a light chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:89; and
a light chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:90.

### Claim 26 (depends on 1, 2, 3, 4, 8, 9, 10, 11, 12, 13, 14)

A protein according to any one of claims 1-4 or 8-14, wherein the second antigen-binding site is a single-domain antibody.

### Claim 27 (depends on 26)

The protein of claim 26, wherein the second antigen-binding site is a VHH fragment or a VNAR fragment.

### Claim 28

A protein according to any one of the preceding claims, wherein the protein comprises a portion of an antibody Fc domain sufficient to bind CD16, wherein the antibody Fc domain comprises hinge and CH2 domains.

### Claim 29 (depends on 28)

A protein according to claim 28, wherein the antibody Fc domain comprises hinge and CH2 domains of a human IgG1 antibody.

### Claim 30 (depends on 28, 29)

A protein according to claim 28 or 29, wherein the Fc domain comprises an amino acid sequence at least 90% identical to amino acids 234-332 of a human IgG1 antibody.

### Claim 31 (depends on 28, 29, 30)

A protein according to any one of claims 28-30, wherein the Fc domain comprises amino acid sequence at least 90% identical to the Fc domain of human IgG1 and differs at one or more positions selected from the group consisting of Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411, K439.

### Claim 32

A formulation comprising a protein according to any one of the preceding claims and a pharmaceutically acceptable carrier.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A cell comprising one or more nucleic acids expressing a protein according to any one of claims 1-31.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A method of directly and/or indirectly enhancing tumor cell death, the method comprising exposing a tumor and natural killer cells to a protein according to any one of claims 1-31.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method of treating cancer, wherein the method comprises administering a protein according to any one of claims 1-31 or a formulation according to claim 32 to a patient.

### Claim 36 (depends on 35)

The method of claim 35, wherein the cancer is selected from the group consisting of multiple myeloma, acute myelomonocytic leukemia, T cell lymphoma, acute monocytic leukemia, and follicular lymphoma.
